US-based obesity firm hires former Novo VP

Ed Cinca, who was behind the launches of Ozempic, Rybelsus and Wegovy at Novo Nordisk, has joined Currax Pharmaceuticals, which also has an obesity drug among its products.

After more than 18 years at Novo Nordisk, Ed Cinca left the Danish pharmaceutical company in July.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading